Back HIV Prevention Microbicides

Microbicides

Dapivirine Vaginal Ring Study Fully Enrolled, New Technology Shows Promise

The Microbicide Trials Network (MTN) announced last week that the Phase 3 ASPIRE trial, testing a vaginal ring containing the NNRTI dapivirine for preventing sexual transmission of HIV, has completed enrollment with more than 2600 women. In related news, researchers reported promising findings from a study of a novel "pod" technology for delivering multiple drugs for HIV prevention in a vagina ring.

alt

Read more:

Microbicide Gel Protects against Vaginal or Anal Transmission of HIV and Other STIs

An experimental microbicide gel known as MZC offers protection against multiple strains of HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV), and it appears safe for either vaginal or rectal use, according to an animal study by researchers at the Population Council.

alt

Read more:

CROI 2014: Dapivirine Vaginal Ring Appears Safe and Effective in Tissue Study

Vaginal rings containing the experimental NNRTI dapivirine were well-tolerated and blocked HIV infection of cervical tissue samples, but rings containing maraviroc did not produce adequate drug concentrations, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

Read more:

CROI 2014: Self-Reports Did Not Reflect Actual Gel or Pill Use in VOICE PrEP Trial

Self-reported adherence to daily tenofovir or Truvada pills or tenofovir vaginal gel for pre-exposure prophylaxis (PrEP) against HIV infection did not match drug levels in the body, helping to explain the lack of protection seen in the VOICE trial, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.

alt

Read more:

HIV Integrase Inhibitor Elvitegravir Approved in European Union

The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.

alt

Read more: